NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq:INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced financial results and operational highlights for the quarter ended March 31, 2022. In addition, the Company provided an overview of recent corporate developments.
Read more at globenewswire.comIN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Computer%20board%20micro%20chip%20green%20by%20blickpixel%20via%20Pixabay.jpg){kind=tracking}
